Clinical Trial Update: Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating adverse events and intravenous ABBV-787 in adults with relapsed/refractory acute myeloid leukemia has been terminated. The sponsor is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ABBV-787

Snippet

Sponsor: AbbVie | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED